Arsanis, a clinical-stage biopharmaceutical company, utilizes monoclonal antibody (mAb) immunotherapies to combat serious infectious diseases. With a deep understanding of infection pathogenesis and access to advanced mAb discovery techniques, Arsanis is building a pipeline of novel mAbs with high potency against their targets. Their lead clinical program, ASN100, focuses on preventing Staphylococcus aureus pneumonia in high-risk patients. Arsanis also has a preclinical pipeline targeting various bacterial and viral pathogens. Headquartered in Massachusetts, USA, Arsanis operates European research and development operations in Vienna, Austria.